Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03834272 · ClinicalTrials.gov registry record · Phase 1
Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies
A Phase 1 study, sponsored by Lumicell.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT03834272: Completed Phase 1 study, sponsored by Lumicell.
NCT03834272 is a Phase 1 study that has completed, run by Lumicell. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03834272, a Phase 1 study, has completed, sponsored by Lumicell.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The objective of this feasibility study is to assess the initial safety and efficacy of the LUM Imaging System for in vivo imaging of metastases to the peritoneum from primary gastrointestinal cancer, ovarian cancer and mesothelioma. This feasibility study consists of a dose escalation phase to select the optimal dose.
Primary Outcome
Correlate the fluorescence levels in tumor tissue imaging to the dose of LUM015 injected.
Interventions
- COMBINATION_PRODUCT LUM Imaging System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-03-18 |
| Est. Completion | 2025-08-19 |
| Phase | Phase 1 |
What the finished NCT03834272 record still lists
NCT03834272 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 1 intervention - of which LUM Imaging System is the first listed.
NCT03834272 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03834272 about?
NCT03834272 is a clinical study titled "Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies". The objective of this feasibility study is to assess the initial safety and efficacy of the LUM Imaging System for in vivo imaging of metastases to the peritoneum from primary gastrointestinal cancer, ovarian cancer and mesothelioma. This feasibility study consists of a dose escalation phase to sele...
What is the current status of trial NCT03834272?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2019-03-18. Estimated completion is 2025-08-19.
What interventions are being tested in trial NCT03834272?
The interventions under investigation include: LUM Imaging System (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03834272?
This trial is sponsored by Lumicell, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03834272's enrollment target sits among peer trials
18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI